Dr. Pennell on Importance of EGFR Testing in NSCLC

Nathan Pennell, MD, PhD
Published: Wednesday, Aug 31, 2016


Nathan Pennell, MD, PhD, associate professor of Medicine at Cleveland Clinic, discusses the importance of testing patients with non–small cell lung cancer (NSCLC) to determine if they harbor the EGFR mutation, as well as the agents available to target that genetic abnormality.

Patients should always be tested for EGFR in the first-line setting, Pennell explains. Additionally, patients should not be treated with an EGFR-targeted agent unless they have the mutation. If they do have the mutation, gefitinib (Iressa), erlotinib (Tarceva), and afatinib (Gilotrif) are the 3 targeted agents available for this population.

For patients who acquire resistance to an EGFR TKI and harbor the T790M resistance mutation, they may be able to receive treatment with the well-tolerated agent osimertinib (Tagrisso). Patients must be biopsied to determine whether they have the T790M mutation, he adds.

Nathan Pennell, MD, PhD, associate professor of Medicine at Cleveland Clinic, discusses the importance of testing patients with non–small cell lung cancer (NSCLC) to determine if they harbor the EGFR mutation, as well as the agents available to target that genetic abnormality.

Patients should always be tested for EGFR in the first-line setting, Pennell explains. Additionally, patients should not be treated with an EGFR-targeted agent unless they have the mutation. If they do have the mutation, gefitinib (Iressa), erlotinib (Tarceva), and afatinib (Gilotrif) are the 3 targeted agents available for this population.

For patients who acquire resistance to an EGFR TKI and harbor the T790M resistance mutation, they may be able to receive treatment with the well-tolerated agent osimertinib (Tagrisso). Patients must be biopsied to determine whether they have the T790M mutation, he adds.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x